...
Performance Outlook.
| Previous Close | 32.09 |
|---|---|
| Bid | 26.75 x 1200 |
| Ask | 32.00 x 900 |
| Day's Range | 31.05 - 32.26 |
| 52 Week Range | 18.69 - 46.46 |
What is rgenix?
Rgenix is a a discovery platform, revolutionizing the treatment of cancer by generating first-in-class therapeutics. Rgenix is a a discovery platform, revolutionizing the treatment of cancer by generating first-in-class therapeutics that target key nodes in cancer progression.
Where can I buy shares of rgnx?
Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Does regenxbio stock pay dividends?
The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland. More... RGNX does not currently pay a dividend.
What does regenxbio do for other companies?
REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases.
3.3 Analyst's Opinion
Is REGENXBIO a buy right now?
REGENXBIO has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
How has REGENXBIO's stock price been impacted by COVID-19?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" REGENXBIO stock. View analyst ratings for REGENXBIO or view top-rated stocks.
When is REGENXBIO's next earnings date?
REGENXBIO's stock was trading at $32.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RGNX shares have decreased by 24.4% and is now trading at $24.86. View which stocks have been most impacted by COVID-19.
How can I listen to REGENXBIO's earnings call?
REGENXBIO is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022. View our earnings forecast for REGENXBIO.
How were REGENXBIO's earnings last quarter?
REGENXBIO will be holding an earnings conference call on Tuesday, March 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
What price target have analysts set for RGNX?
REGENXBIO Inc. (NASDAQ:RGNX) announced its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($1.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by $0.50.
Recently Viewed Tickers
7 Wall Street analysts have issued 1 year price objectives for REGENXBIO's shares. Their forecasts range from $17.00 to $90.00. On average, they expect REGENXBIO's stock price to reach $52.00 in the next twelve months.
No Recent Tickers
Visit a quote page and your recently viewed tickers will be displayed here.
What is RegeneRx Biopharmaceuticals?
Visit a quote page and your recently viewed tickers will be displayed here.
What is RegeneRx? What is its purpose?
(OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, is addressing rumors in the market regarding its ARISE-3 phase 3 dry eye trial.
Is RegeneRx a joint venture?
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the estimated timing of the statistical and regulatory plan for its phase 3 dry eye clinical trial (ARISE-3). This summary was provided to RegeneRx by GtreeBNT, the operating entity of its U.S. joint venture, ReGenTree LLC and sponsor of the ARISE-3 trial, which was generated at GtreeBNT's shareholder meeting on Friday March 19, 2021: http://www.regenerx.com/March-22-2021-Update-on-ARISE-3-Statistical-and-Regulatory-Plan or navigate to RegeneRx's home page at http://www.regenerx.com.
